Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery
-
Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery
-
Alcon picks Geneva over Texas for new HQ
-
Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
-
Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo
-
Pre-Open Movers 08/29: (GKOS) (TLRY) (SPHS) (EXPR) Higher; (AEO) (DKS) (ROKU) Lower
-
Glaukos Corporation (GKOS) Gains After Alcon (NVS) Announces Withdrawal of CyPass Micro-Stent from Market
-
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
-
Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics
-
MerLion Regains North American Rights to XTOROTM FDA-Approved Antibiotic for Treatment of Ear Infections
-
Alcon introduces NGENUITY® 3D Visualization System with DATAFUSION™ to simplify, customize vitreoretinal surgery
-
Novartis (NVS) Tops Q2 EPS by 2c (Earlier)
-
Novartis hints at 2018 outlook hike despite drug price freeze
-
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
-
Sinovant Sciences, Company Focused on the Development of Innovative Medicines in China, Unveiled at Event in Beijing
-
Novartis chairman says Alcon worth $20 billion-$30 billion: Finanz und Wirtschaft
-
Novartis (NVS) to Spinoff Alcon (Earlier)
-
Novartis hands investors Alcon spin-off, $5 billion share buyback
-
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
-
uStudio Introduces First Secure Podcast Solution for Private Enterprise Communications
-
Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
-
Earth Science Laboratories Expands Research and Development
-
Alcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
-
Novartis top lawyer exits over Trump attorney deal 'mistake'
-
At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
-
UBS poaches investment banker Illy from Credit Suisse
-
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
-
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
-
Alcon Introduces AIR OPTIX® COLORS Contact Lenses Gemstone Collection, Creating New Ways to Enhance and Play with Eye Color
-
ViewPoint Appoints Dr. Robert Kim as Chief Medical Officer
-
Lysogene Strengthens Board of Directors with Appointment of Dr. Peter Lichtlen
-
Lysogene Strengthens Board of Directors with Appointment of Dr. Peter Lichtlen
-
Novartis (NVS) Misses Q1 EPS by 1c, Revenue Beats
-
Novartis CEO feels heat on U.S. generics, Cosentyx drop
-
Novartis delivered a strong first quarter and acted to become a more focused medicines company
-
Alcon introduces pre-loaded delivery system for the CyPass® Micro-Stent to enhance surgical experience
-
New Review of Dry Eye Disease - Current Insights and Future Perspectives - touchOPHTHALMOLOGY
-
New Review of Early Clinical Experiences with Brinzolamide/Brimonidine Fixed Combination in Open-angle Glaucoma and Ocular Hypertension - touchOPHTHALMOLOGY
-
New Review of Modern Perspectives on Dry Eye Disease - touchOPHTHALMOLOGY
-
Hoodoo Digital Brings Next Generation Media Capabilities to Adobe Experience Manager
-
GSK buys out Novartis in $13 billion consumer healthcare shake-up
-
ThromboGenics Business Update - FY 2017
-
ThromboGenics Business Update - FY 2017
-
Back of the Eye Disorders, Featuring a Steadily Growing Pipeline, Likely to Witness 7.9% Annualized Growth, Predicts Roots Analysis
-
Greek parliament to probe politicians in alleged Novartis bribe case
-
uStudio Expands Enterprise Portfolio
-
2017 Annual Results
-
Performance Health Appoints Jeff George as Chief Executive Officer
-
Novartis (NVS) PT Raised to $100 at Leerink Partners
-
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase

